Unicycive Therapeutics (UNCY)
(Delayed Data from NSDQ)
$3.96 USD
-0.13 (-3.18%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.98 +0.02 (0.51%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
UNCY 3.96 -0.13(-3.18%)
Will UNCY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for UNCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UNCY
DaVita Stock Declines 1.2% in 3 Months: Here's How to Play
UNCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for UNCY
UNCY forms Bollinger Band Squeeze on September 20
Is UNCY consolidating before a move? Bollinger Band Squeeze shows up after climbing 1.24%
NR7 appears for UNCY after 1.25% move
UNCY forms 20 Day Moving Average Resistance on September 16
Is UNCY likely to continue lower? Stochastic Reached Oversold shows up after gaining 1.81%